Person · CIK 1860609

Sushil Patel

Chief Executive Officer at Replimune Group; director at Revolution Medicines

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$3.3M

Noticed on Form 144$2.3M

Bought on Form 4$0

Companies2

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Replimune Group REPL	Common Stock	Directly	708,151	Aug 10, 2026 · Filing · EDGAR
Replimune Group REPL	Employee Stock Option (right to buy) exercise $7.61, expires Apr 1, 2036, into Common Stock	Directly	376,860	Apr 1, 2026 · Filing · EDGAR
Revolution Medicines RVMD	Common Stock	Directly	21,656	Jun 29, 2026 · Filing · EDGAR
Revolution Medicines RVMD	Stock Option (Right to Buy) exercise $37.54, expires Jun 19, 2034, into Common Stock	Directly	13,000	Jun 29, 2026 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2026	$510K	—
Q2 2026	$1.2M	$1M
Q4 2025	$111K	$111K
Q2 2025	$202K	—
Q4 2024	$395K	$441K
Q3 2024	$95K	$85K
Q2 2024	$210K	$71K
Q2 2023	$418K	$556K
Q2 2022	$156K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Mar 30, 2026 · 1 notice
Jun 29, 2026	5,580 · ~$1M	Jun 29, 2026	Sold as noticed Sold 5,580 in 9 sales, Jun 29 to Jun 29 · $1M Form 4	Filing · EDGAR
Replimune Group REPL · J.P. Morgan Securities · 10b5-1 plan adopted Jun 2, 2025 · 1 notice
Dec 2, 2025	10,000 · ~$111K	Dec 2, 2025	Sold as noticed Sold 10,000 at $11.13 on Dec 2 · $111K Form 4	Filing · EDGAR
Replimune Group REPL · J.P. Morgan Securities · 10b5-1 plan adopted Apr 3, 2024 · 1 notice
Dec 16, 2024	15,000 · ~$189K	Dec 16, 2024	Partly sold Sold 10,000 at $12.42 on Dec 16 · $124K likely match Form 4	Filing · EDGAR
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 7, 2023 · 1 notice
Oct 31, 2024	5,000 · ~$253K	Oct 31, 2024	Sold as noticed Sold 5,000 at $54.14 on Oct 31 · $271K Form 4	Filing · EDGAR
Revolution Medicines RVMD · Morgan Stanley Smith Barney · 10b5-1 plan adopted Sep 6, 2023 · 2 notices
Jul 9, 2024	2,155 · ~$85K	Jul 9, 2024	Sold as noticed Sold 2,155 at $44.00 on Jul 9 · $95K Form 4	Filing · EDGAR
Apr 10, 2024	2,155 · ~$71K	Apr 10, 2024	Sold as noticed Sold 2,155 at $37.00 on Apr 10 · $80K Form 4	Filing · EDGAR
Replimune Group REPL · J.P. Morgan Securities · 10b5-1 plan adopted Mar 15, 2023 · 1 notice
Jun 13, 2023	23,710 · ~$556K	Jun 13, 2023	Partly sold Sold 5,698 in 2 sales, Jun 13 to Jun 13 · $137K likely match Form 4	Filing · EDGAR
Sales without a matching Form 144 · 6 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Replimune Group (REPL): Sold 39,341 at $12.97 on Aug 10, 2026 · $510K	Filing · EDGAR
—	—	—	Sold without notice Replimune Group (REPL): Sold 37,324 at $5.08 on May 18, 2026 · $190K	Filing · EDGAR
—	—	—	Sold without notice Replimune Group (REPL): Sold 25,105 at $8.06 on May 20, 2025 · $202K	Filing · EDGAR
—	—	—	Sold without notice Replimune Group (REPL): Sold 20,194 at $6.47 on May 16, 2024 · $131K	Filing · EDGAR
—	—	—	Sold without notice Replimune Group (REPL): Sold 15,575 at $18.05 on May 16, 2023 · $281K	Filing · EDGAR
—	—	—	Notice not machine-readable Replimune Group (REPL): Sold 10,687 at $14.59 on May 16, 2022 · $156K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Replimune Group REPL Chief Executive Officer · filings 2021 to 2026 · sold $1.8M · $856K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 10, 2026	Open-market or private sale	−39,341	$12.97	$510K	708,151 direct	Filing · EDGAR
May 18, 2026	Open-market or private sale	−37,324	$5.08	$190K	747,492 direct	Filing · EDGAR
Apr 1, 2026	Grant or award from the company	+251,240			784,816 direct	Filing · EDGAR
Apr 1, 2026	Grant or award from the company Employee Stock Option (right to buy)	+376,860			376,860 direct	Filing · EDGAR
Dec 19, 2025	Grant or award from the company	+200,000			533,576 direct	Filing · EDGAR
Dec 2, 2025	Sale under a 10b5-1 plan	−10,000	$11.13	$111K	333,576 direct	Filing · EDGAR
May 20, 2025	Open-market or private sale	−25,105	$8.06	$202K	343,576 direct	Filing · EDGAR
Apr 1, 2025	Grant or award from the company	+166,667			368,681 direct	Filing · EDGAR
Apr 1, 2025	Grant or award from the company Employee Stock Option (right to buy)	+250,000			250,000 direct	Filing · EDGAR
Dec 16, 2024	Sale under a 10b5-1 plan	−10,000	$12.42	$124K	202,014 direct	Filing · EDGAR
May 16, 2024	Open-market or private sale	−20,194	$6.47	$131K	212,014 direct	Filing · EDGAR
Apr 1, 2024	Grant or award from the company	+83,335			232,208 direct	Filing · EDGAR
Apr 1, 2024	Grant or award from the company Employee Stock Option (right to buy)	+250,000			250,000 direct	Filing · EDGAR
Jun 13, 2023	Sale under a 10b5-1 plan	−5,145	$24.11	$124K	149,426 direct	Filing · EDGAR
Jun 13, 2023	Sale under a 10b5-1 plan	−553	$23.44	$13K	148,873 direct	Filing · EDGAR
May 16, 2023	Open-market or private sale	−15,575	$18.05	$281K	154,571 direct	Filing · EDGAR
Apr 1, 2023	Grant or award from the company	+40,000			170,146 direct	Filing · EDGAR
Apr 1, 2023	Grant or award from the company Employee Stock Option (right to buy)	+60,000			60,000 direct	Filing · EDGAR
May 16, 2022	Open-market or private sale	−10,687	$14.59	$156K	130,146 direct	Filing · EDGAR
Apr 1, 2022	Grant or award from the company	+52,500			140,833 direct	Filing · EDGAR
Apr 1, 2022	Grant or award from the company Employee Stock Option (right to buy)	+78,750			78,750 direct	Filing · EDGAR
May 3, 2021	Grant or award from the company	+88,333			88,333 direct	Filing · EDGAR
May 3, 2021	Grant or award from the company Employee Stock Option (right to buy)	+125,000			125,000 direct	Filing · EDGAR

Revolution Medicines RVMD Director · filings 2022 to 2026 · sold $1.5M · $1.4M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 29, 2026	Option or RSU exercised or converted	+2,955	$37.54	$111K	27,236 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−300	$183.17	$55K	26,936 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−900	$184.59	$166K	26,036 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−1,100	$185.90	$204K	24,936 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−858	$186.92	$160K	24,078 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−300	$187.83	$56K	23,778 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−100	$188.57	$19K	23,678 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−600	$190.55	$114K	23,078 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−541	$191.87	$104K	22,537 direct	Filing · EDGAR
Jun 29, 2026	Sale under a 10b5-1 plan	−881	$192.61	$170K	21,656 direct	Filing · EDGAR
Jun 29, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,955			13,000 direct	Filing · EDGAR
Jun 18, 2026	Grant or award from the company	+1,191			24,281 direct	Filing · EDGAR
Jun 18, 2026	Grant or award from the company Stock Option (Right to Buy)	+3,127			3,127 direct	Filing · EDGAR
Jun 26, 2025	Grant or award from the company	+3,142			23,090 direct	Filing · EDGAR
Jun 26, 2025	Grant or award from the company Stock Option (Right to Buy)	+11,574			11,574 direct	Filing · EDGAR
Oct 31, 2024	Option or RSU exercised or converted	+5,000	$24.84	$124K	24,948 direct	Filing · EDGAR
Oct 31, 2024	Sale under a 10b5-1 plan	−5,000	$54.14	$271K	19,948 direct	Filing · EDGAR
Oct 31, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			13,400 direct	Filing · EDGAR
Jul 9, 2024	Option or RSU exercised or converted	+2,155	$16.80	$36K	22,103 direct	Filing · EDGAR
Jul 9, 2024	Sale under a 10b5-1 plan	−2,155	$44.00	$95K	19,948 direct	Filing · EDGAR
Jul 9, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,155			32,490 direct	Filing · EDGAR
Jun 20, 2024	Grant or award from the company	+4,248			19,948 direct	Filing · EDGAR
Jun 20, 2024	Grant or award from the company Stock Option (Right to Buy)	+15,955			15,955 direct	Filing · EDGAR
Apr 10, 2024	Option or RSU exercised or converted	+2,155	$16.80	$36K	17,855 direct	Filing · EDGAR
Apr 10, 2024	Sale under a 10b5-1 plan	−2,155	$37.00	$80K	15,700 direct	Filing · EDGAR
Apr 10, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,155			34,645 direct	Filing · EDGAR
Jun 8, 2023	Grant or award from the company	+5,200			15,700 direct	Filing · EDGAR
Jun 8, 2023	Grant or award from the company Stock Option (Right to Buy)	+18,400			18,400 direct	Filing · EDGAR
Jun 16, 2022	Grant or award from the company	+10,500			10,500 direct	Filing · EDGAR
Jun 16, 2022	Grant or award from the company Stock Option (Right to Buy)	+36,800			36,800 direct	Filing · EDGAR

All 35 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Aug 12, 2026	Form 4	Replimune Group REPL	Filing · EDGAR
Jul 1, 2026	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Jun 29, 2026	Form 144	Revolution Medicines RVMD	Filing · EDGAR
Jun 23, 2026	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 20, 2026	Form 4	Replimune Group REPL	Filing · EDGAR
Apr 7, 2026	Form 4	Replimune Group REPL	Filing · EDGAR
Dec 19, 2025	Form 4	Replimune Group REPL	Filing · EDGAR
Dec 4, 2025	Form 4	Replimune Group REPL	Filing · EDGAR
Dec 2, 2025	Form 144	Replimune Group REPL	Filing · EDGAR
Jun 30, 2025	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 22, 2025	Form 4	Replimune Group REPL	Filing · EDGAR
Apr 3, 2025	Form 4	Replimune Group REPL	Filing · EDGAR
Dec 18, 2024	Form 4	Replimune Group REPL	Filing · EDGAR
Dec 16, 2024	Form 144	Replimune Group REPL	Filing · EDGAR
Nov 4, 2024	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Oct 31, 2024	Form 144	Revolution Medicines RVMD	Filing · EDGAR
Jul 10, 2024	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Jul 9, 2024	Form 144	Revolution Medicines RVMD	Filing · EDGAR
Jun 28, 2024	Form 4/A	Revolution Medicines RVMD	Filing · EDGAR
Jun 24, 2024	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 20, 2024	Form 4	Replimune Group REPL	Filing · EDGAR
Apr 12, 2024	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Apr 10, 2024	Form 144	Revolution Medicines RVMD	Filing · EDGAR
Apr 3, 2024	Form 4	Replimune Group REPL	Filing · EDGAR
Jun 15, 2023	Form 4	Replimune Group REPL	Filing · EDGAR
Jun 13, 2023	Form 144	Replimune Group REPL	Filing · EDGAR
Jun 12, 2023	Form 4	Revolution Medicines RVMD	Filing · EDGAR
May 18, 2023	Form 4	Replimune Group REPL	Filing · EDGAR
Apr 4, 2023	Form 4	Replimune Group REPL	Filing · EDGAR
Jun 17, 2022	Form 4	Revolution Medicines RVMD	Filing · EDGAR
Jun 17, 2022	Form 3	Revolution Medicines RVMD	Filing · EDGAR
May 18, 2022	Form 4	Replimune Group REPL	Filing · EDGAR
Apr 5, 2022	Form 4	Replimune Group REPL	Filing · EDGAR
May 5, 2021	Form 4	Replimune Group REPL	Filing · EDGAR
May 5, 2021	Form 3	Replimune Group REPL	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.